Doaa Esmaeil | Cancer treatment | Best Researcher Award

Posted on by sciencefather

Assoc. Prof. Dr. Doaa Esmaeil | Cancer treatment | Best Researcher Award

Assoc. Prof. Dr. Doaa Esmaeil , Mansoura university , Egypt

Dr. Doaa Abd Elmoneim Mohamed Esmaeil is an Associate Professor of Oral Pathology at Mansoura University, Egypt. She is a dedicated researcher focused on oral diseases, particularly in understanding their pathogenesis, molecular biology, and carcinogenesis. With a strong background in oral pathology, she has contributed to numerous studies and publications that explore various aspects of oral health, including cancer research and therapeutic strategies. Dr. Esmaeil’s research includes innovative work on the effects of different agents and treatments in combating oral diseases. Her extensive academic contributions have established her as a prominent figure in the field of oral pathology, both in Egypt and internationally. She is committed to advancing the understanding of oral diseases, particularly those linked to cancer, and plays an active role in advancing the knowledge of oral health practices.

Publication Profile:

Orcid

Strengths for the Award:

  1. Academic Excellence: Dr. Doaa Esmaeil is an Associate Professor in the Oral Pathology Department at Mansoura University, Egypt, with a strong academic background and expertise in oral diseases, particularly oral carcinogenesis and molecular biology. Her contributions to the scientific community through both teaching and research have made her a significant figure in the field.

  2. Research Contributions: Dr. Esmaeil has made notable contributions to oral pathology through her innovative research on molecular mechanisms in oral diseases, focusing on cancer pathogenesis, therapeutic agents, and disease prevention. Her research projects, such as exploring the efficacy of phytomedicines against chemotherapy-induced toxicity, demonstrate her commitment to improving therapeutic outcomes.

  3. International Recognition: She has published several papers in high-impact journals such as the European Journal of Dentistry, Saudi Dental Journal, and the Egyptian Dental Journal, showcasing her widespread impact in the field of oral pathology.

  4. Ongoing Contributions to the Field: Dr. Esmaeil’s research is forward-thinking, addressing cutting-edge topics like stem cells in oral cancer therapy, the role of molecular markers in oral diseases, and enhancing chemotherapeutic efficacy against head and neck cancers.

Areas for Improvement:

  1. Citation Impact: While Dr. Esmaeil has been an active researcher with publications in reputed journals, her citation index of 3, while a good start, could benefit from increased visibility and collaborations with larger research networks to elevate her work’s recognition and citation in the broader academic community.

  2. Industry Collaborations: Although Dr. Esmaeil’s academic and research work is notable, there appears to be limited documented collaboration with industry projects or patents. Strengthening connections with industry could help translate her research into practical applications, potentially enhancing the impact of her work.

  3. Multidisciplinary Collaboration: While Dr. Esmaeil has collaborated with researchers within the field of oral pathology, expanding these collaborations into multidisciplinary domains could provide a more comprehensive approach to her research and open new avenues for funding and innovation.

Education:

Dr. Doaa Abd Elmoneim Mohamed Esmaeil earned her Bachelor’s degree in Dental Medicine from Mansoura University, Egypt. She then pursued her Master’s and Ph.D. degrees in Oral Pathology, also from Mansoura University, where she developed a keen interest in the molecular mechanisms of oral diseases. Her academic journey has been enriched by her work on various research projects exploring oral carcinogenesis, molecular biology, and the development of therapeutic strategies for oral cancers. Dr. Esmaeil’s dedication to research and her extensive educational background have established her as an expert in oral pathology. She has participated in numerous international and national conferences, strengthening her expertise in both academic and clinical settings. Her education and commitment to continuous learning have shaped her approach to understanding and treating oral diseases, and she remains an influential educator and researcher at Mansoura University.

Experience:

Dr. Doaa Abd Elmoneim Mohamed Esmaeil has over a decade of experience in teaching and researching in the field of oral pathology. As an Associate Professor in the Oral Pathology Department at Mansoura University, she has played a pivotal role in educating undergraduate and postgraduate students in both theoretical and practical aspects of oral pathology. Her experience extends to leading numerous research projects in oral diseases, with a special focus on oral cancer, its molecular mechanisms, and therapeutic approaches. Dr. Esmaeil’s work on tissue biomarkers, cancer stem cells, and chemotherapeutic agents has been recognized internationally. Additionally, her role as a reviewer for several scientific journals has solidified her standing as a respected authority in oral pathology. Her collaborative projects with other universities and institutions, both local and international, have further enhanced her research expertise. Dr. Esmaeil’s passion for education and research continues to shape the future of oral pathology.

Research Focus:

Dr. Doaa Abd Elmoneim Mohamed Esmaeil’s research primarily focuses on the molecular pathogenesis of oral diseases, with a particular emphasis on oral cancer. Her work explores the complex mechanisms underlying carcinogenesis in the oral cavity, particularly focusing on the molecular markers, cell lines, and signaling pathways involved in cancer progression. Dr. Esmaeil is also interested in developing innovative therapeutic strategies for oral diseases, with research exploring the efficacy of various agents, including phytomedicines and synthetic compounds, against oral cancer and other related disorders. Her ongoing research examines the effectiveness of combining traditional treatments with new molecular-targeted therapies to improve patient outcomes. Additionally, she has investigated the role of cancer stem cells in therapy resistance and the development of new treatment modalities. Dr. Esmaeil’s research contributes to the broader understanding of oral diseases, aiming to improve both prevention and treatment options for conditions like oral squamous cell carcinoma.

Publication Top Notes:

  • The Impact of Silver Diamine Fluoride and Potassium Iodide Treatment on Microtensile Bonds Strength of Composite Restoration for Carious Dentin in Primary and Permanent Teeth and Its Potential Color Changes: An in Vitro Study 📄🦷

  • Antitumoral properties of the pomegranate peel and blueberry extracts against tongue carcinoma (in vitro study) 🍊🍇🦷

  • Oral squamous cell carcinoma Immunohistochemical Expression of PD L1 in Oral Epithelial Dysplasia 🦷🔬

  • Stem Cell Marker as A Factor for The Different Biological Behavior of Ameloblastoma and Odontogenic Keratocyst 🧬🦷

  • Diagnostic Value of Nuclear Receptor Subfamily 4 Group A Member 3 in Salivary Gland Carcinomas 🔬🦷

  • The controversial role of MDM2, MCM3 and Bcl-X in Ameloblastoma and Ameloblastic Carcinoma: An update 🧬🦷

  • Pomegranate molasses and red grape vinegar: can they alleviate dysplastic changes in chemically induced oral squamous cell carcinoma in hamsters? 🍑🍇🦷

  • Tumor stroma ratio as a parameter for prognosis and clinicopathological behavior of oral squamous cell carcinoma: A retrospective cohort study 📊🦷

  • Emerging therapeutic modality enhancing the efficiency of chemotherapeutic agents against head and neck squamous cell carcinoma cell lines 💊🦷

  • Angiogenesis and mast cells as predictive factors in behavior of Odontogenic cysts 🌱🦷

Conclusion:

Dr. Doaa Abd Elmoneim Mohamed Esmaeil is highly deserving of the Best Researcher Award. Her academic excellence, profound contributions to oral pathology, and commitment to advancing the understanding of oral diseases and cancer pathogenesis make her a strong candidate. By focusing on broadening her citation impact and enhancing her industry collaborations, Dr. Esmaeil has the potential to elevate her career to even greater heights. Her continued research and dedication to the scientific community position her as an influential researcher in the field of oral pathology, contributing not only to academia but also to real-world applications in oral healthcare.

Huining He | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Huining He | Cancer Cell Biology | Best Researcher Award

Prof. Huining He , School of Biomedical Engineering and Technology, Tianjin Medical University , China

Dr. Huining He is a prominent Professor and the Dean of the School of Biomedical Engineering and Technology at Tianjin Medical University, China. With a Ph.D. in Chemical Engineering from Tianjin University, she completed joint research at the University of Michigan. Her career spans across significant achievements in biomedical engineering, specializing in biomaterials, drug delivery systems, and cancer therapy. She has been recognized with prestigious awards, including the “Young Changjiang Scholar” and the “Tianjin Science Fund for Outstanding Young Scholars.” As an active member of various academic societies and a board member of the Asian Journal of Pharmaceutical Sciences, she fosters international collaboration and academic advancement. Her research has garnered substantial contributions to the field of biomedical engineering, with numerous patents and high-impact publications in cancer treatment and drug delivery systems.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Huining He is an outstanding researcher with a strong academic and professional background. As a Professor and Dean at Tianjin Medical University, she leads the School of Biomedical Engineering and Technology with a focus on cutting-edge biomedical research, particularly in biomaterials and drug delivery systems. Her innovative work in the development of enzyme-sensitive targeted systems for gene therapy and prodrug-type macromolecular drug delivery for colon cancer is a key contribution to the field. Additionally, her leadership in several projects funded by the National Natural Science Foundation of China, particularly those targeting glioma treatment, showcases her ability to translate research into impactful clinical applications.

Dr. He’s collaboration with international and domestic institutions further enhances her research impact. She is well-regarded for pioneering novel drug delivery systems and has made notable contributions through numerous high-quality publications, which have earned her an H-index of 21 and six authorized patents. She also actively participates in academic exchanges and professional networks, serving as a member of editorial boards and scientific committees.

Areas for Improvements:

While Dr. He has made remarkable strides in biomedical engineering, there are areas where further focus could amplify her impact:

  1. Broader Clinical Application: The continued translation of her drug delivery systems into clinical settings could benefit from additional industry partnerships and clinical trials.
  2. Interdisciplinary Collaboration: Expanding her work to incorporate emerging fields such as artificial intelligence in drug delivery systems could lead to more personalized treatment solutions.
  3. Public Engagement: Increasing public awareness of her research through media and outreach could bridge the gap between academia and the general public, facilitating broader societal impact.

Education:

Dr. Huining He earned her Ph.D. in Chemical Engineering from Tianjin University, where she gained profound expertise in biomaterials and drug delivery systems. During her doctoral studies, she participated in joint training at the University of Michigan, an experience that greatly expanded her research skills and international perspective. This training allowed her to engage in cutting-edge projects in the fields of biomaterials and drug delivery. Her advanced education laid the foundation for her future contributions to biomedical engineering, especially in the development of novel targeted systems for gene therapy and cancer treatment. Dr. He’s academic journey has been marked by strong mentorship, international collaborations, and her leadership role in several research projects that have significantly advanced the biomedical field.

Experience:

Dr. Huining He’s career in biomedical engineering spans extensive academic and research experience. Currently, as the Dean of the School of Biomedical Engineering and Technology at Tianjin Medical University, she leads a dynamic department focused on advancing healthcare solutions through innovative research. She has supervised numerous Ph.D. students, guiding them in pioneering research on biomaterials and drug delivery systems. Her work has been recognized by the Ministry of Education, with prestigious titles such as the “Young Changjiang Scholar.” Dr. He has led and contributed to several high-profile research projects funded by China’s National Natural Science Foundation, including investigations into enzyme-sensitive targeted systems for gene therapy and glioma treatment. Beyond academia, she has participated in industry projects, translating her research into real-world applications. As a member of numerous professional organizations and editorial boards, Dr. He plays a vital role in facilitating international collaborations and advancing scientific knowledge in the biomedical sector.

Research Focus:

Dr. Huining He’s research focuses on the design and development of advanced biomaterials and drug delivery systems, particularly in the treatment of cancer and other serious diseases. Her work involves creating innovative, targeted drug delivery systems that can enhance the efficacy and precision of treatment. She has conducted pivotal studies on enzyme-sensitive targeted systems for gene therapy, improving the delivery of therapeutic agents to cancer cells. Currently, Dr. He is leading several projects on siRNA co-delivery systems for glioma, investigating ways to overcome the challenges in glioma treatment. Her research also covers the development of prodrug-type macromolecular systems and multifunctional exosome-based drug delivery technologies. Dr. He’s work has the potential to revolutionize cancer treatment and other therapeutic approaches, contributing to the development of more efficient, less toxic therapies for patients. Her research continues to make substantial advancements in the fields of drug delivery, biomedical engineering, and cancer therapy.

Publications Top Notes:

  1. CaCO3-based nanomedicine with multi-functions of ferroptosis-apoptosis and microenvironment regulation in cancer 🔬💡 (Nano Today, 2025)
  2. Lipid Nanoparticular Codelivery System for Enhanced Antitumor Effects by Ferroptosis-Apoptosis Synergistic with Programmed Cell Death-Ligand 1 Downregulation 🧬⚡ (ACS Nano, 2024)
  3. Nanomedicine integrating the lipidic derivative of 5-fluorouracil, miriplatin and PD-L1 siRNA for enhancing tumor therapy 💊🧪 (Chinese Chemical Letters, 2024)
  4. A review on gold nanoparticles as an innovative therapeutic cue in bone tissue engineering: Prospects and future clinical applications 🏥🔬 (Materials Today Bio, 2024)
  5. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment 🧬🔗 (Journal of Controlled Release, 2024)
  6. An injectable signal-amplifying device elicits a specific immune response against malignant glioblastoma 💉🧠 (Acta Pharmaceutica Sinica B, 2023)
  7. Antitumor synergism between PAK4 silencing and immunogenic phototherapy of engineered extracellular vesicles 🧬💥 (Acta Pharmaceutica Sinica B, 2023)
  8. Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence 💧⚔ (Journal of Controlled Release, 2022)
  9. Antibody–siRNA conjugates (ARC): Emerging siRNA drug formulation 🧬💉 (Medicine in Drug Discovery, 2022)
  10. mRNA vaccines for COVID-19 and diverse diseases 💉🦠 (Journal of Controlled Release, 2022)

Conclusion:

Dr. Huining He’s exceptional contributions to the field of biomedical engineering, particularly in the development of novel drug delivery systems for cancer treatment, position her as an ideal candidate for the Best Researcher Award. Her innovative work, combined with a clear vision for the future of precision medicine, continues to drive the field forward. She has the potential to further revolutionize medical treatments, making her a deserving nominee for this prestigious recognition.